SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

SANES

10.708

+0.19%↑

BBVA

19.545

-0.79%↓

BNP

93.59

-0.52%↓

CABK

11.515

-0.6%↓

INGA

26.21

-1.3%↓

Начало・Списък с акции・Ipsen SA.

Ipsen SA.

Отворен

СекторФинансови

155.6 2.64

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

151.4

Максимум

154.9

Ключови измерители
By Trading Economics
Приходи	-225M 110M
Продажби	36M 1.9B
P/E Средно за сектора	28.534 41.721
Дивидентна доходност	0.89
Марж на печалбата	5.899
Служители	5,535
EBITDA	-171M 466M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-5.58% downside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	0.89% 4.65%
Следващи печалби	30.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	1.1B 13B
Предишно отваряне	152.96
Предишно затваряне	155.6

Настроения в новините

By Acuity

42%

58%

120 / 439 Класиране в Finance

Ipsen SA. Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.06.2026 г., 21:51 ч. UTC

Значими двигатели на пазара

Merlin Shares Rally After Defense Department's Design Review Wraps

4.06.2026 г., 23:46 ч. UTC

Пазарно говорене

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4.06.2026 г., 23:44 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4.06.2026 г., 23:42 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4.06.2026 г., 23:41 ч. UTC

Придобивния, сливания и поглъщания

Energy Resources of Australia to Enter Trading Halt

4.06.2026 г., 23:34 ч. UTC

Пазарно говорене

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4.06.2026 г., 23:31 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.06.2026 г., 23:08 ч. UTC

Пазарно говорене

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4.06.2026 г., 22:41 ч. UTC

Пазарно говорене

Australia Shares Set to Rise at the Open -- Market Talk

4.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 20:44 ч. UTC

Придобивния, сливания и поглъщания

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4.06.2026 г., 20:16 ч. UTC

Пазарно говорене

Mexican Demand Indicators Show Signs of Life -- Market Talk

4.06.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4.06.2026 г., 19:46 ч. UTC

Пазарно говорене

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4.06.2026 г., 19:38 ч. UTC

Пазарно говорене

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4.06.2026 г., 19:30 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4.06.2026 г., 18:47 ч. UTC

Придобивния, сливания и поглъщания

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4.06.2026 г., 18:38 ч. UTC

Печалби

Money Quote: Tech Weakness in Context -- WSJ

4.06.2026 г., 18:24 ч. UTC

Печалби

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 17:09 ч. UTC

Пазарно говорене

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4.06.2026 г., 16:58 ч. UTC

Печалби

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4.06.2026 г., 16:46 ч. UTC

Пазарно говорене

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4.06.2026 г., 16:38 ч. UTC

Печалби

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

4.06.2026 г., 16:13 ч. UTC

Пазарно говорене

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4.06.2026 г., 16:11 ч. UTC

Пазарно говорене

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4.06.2026 г., 15:56 ч. UTC

Пазарно говорене

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ipsen SA. Прогноза

Ценова цел

By TipRanks

-5.58% надолу

12-месечна прогноза

Среден 143.8 EUR -5.58%

Висок 170 EUR

Нисък 117 EUR

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Ipsen SA. през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на Ipsen SA. през последните 3 месеца.

Настроение

By Acuity

120 / 439 Класиране в Финансови

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.